Phase II study of sorafenib in patients with relapsed or refractory lymphoma
British Journal of Haematology, 05/14/2012Guidetti A et al.
Compared with patients with progressive disease (PD), responsive patients had significantly higher baseline levels of extracellular signal–regulated kinase phosphorylation and autophagy and presented a significant reduction of these parameters after 1 month of therapy. Sorafenib was well tolerated and had a clinical activity that warrants development of combination regimens.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.